本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Immix Biopharma, Inc

8.52
-0.2800-3.18%
盤後8.520.00000.00%19:34 EDT
成交量:231.88萬
成交額:2,013.87萬
市值:6.07億
市盈率:-9.59
高:8.99
開:8.88
低:8.48
收:8.80
52周最高:12.14
52周最低:1.94
股本:7,119.00萬
流通股本:5,678.11萬
量比:1.13
換手率:4.08%
股息:- -
股息率:- -
每股收益(TTM):-0.8883
每股收益(LYR):-0.8930
淨資產收益率:-74.47%
總資產收益率:-38.97%
市淨率:7.19
市盈率(LYR):-9.54

資料載入中...

2026/07/20

重要事件披露

Form 8-K - Current report
2026/06/05

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/29

重要事件披露

Form 8-K - Current report
2026/05/21

重要事件披露

Form 8-K - Current report
2026/05/21

[補充]招股説明書

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2026/05/21

重要事件披露

Form 8-K - Current report
2026/05/15

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/07

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/05

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/03/30

重要事件披露

Form 8-K - Current report
2026/03/27

[修訂]年度報告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2026/03/25

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/25

重要事件披露

Form 8-K - Current report
2026/03/25

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/01/17

SEC問詢函

Form CORRESP - Correspondence
2025/12/08

重要事件披露

Form 8-K - Current report
2025/12/08

[補充]招股説明書

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2025/12/08

重要事件披露

Form 8-K - Current report
2025/11/27

SEC問詢函

Form CORRESP - Correspondence
2025/11/26

重要事件披露

Form 8-K - Current report